SARS-CoV-2 neutralizing antibody responses are more robust in patients with severe disease

被引：87

作者：

Wang, Pengfei ^{[1
]}

Liu, Lihong ^{[1
]}

Nair, Manoj S. ^{[1
]}

Yin, Michael T. ^{[2
]}

Luo, Yang ^{[1
]}

Wang, Qian ^{[3
]}

Yuan, Ting ^{[1
]}

Mori, Kanako ^{[1
]}

Solis, Axel Guzman ^{[1
]}

Yamashita, Masahiro ^{[1
]}

Garg, Ankur ^{[4
]}

Purpura, Lawrence J. ^{[2
]}

Laracy, Justin C. ^{[2
]}

Yu, Jian ^{[1
]}

Joshua-Tor, Leemor ^{[4
]}

Sodroski, Joseph ^{[3
]}

Huang, Yaoxing ^{[1
]}

Ho, David D. ^{[1
]}

机构：

[1] Columbia Univ, Vagelos Coll Phys & Surg, Aaron Diamond AIDS Res Ctr, 701 W 168th St, New York, NY 10032 USA

[2] Columbia Univ, Vagelos Coll Phys & Surg, Dept Internal Med, Div Infect Dis, New York, NY USA

[3] Harvard Med Sch, Dept Microbiol, Dana Farber Canc Inst, Dept Canc Immunol & Virol, Boston, MA 02115 USA

[4] Cold Spring Harbor Lab, WM Keck Struct Biol Lab, POB 100, Cold Spring Harbor, NY 11724 USA

来源：

EMERGING MICROBES & INFECTIONS | 2020年 / 9卷 / 01期

基金：

美国国家卫生研究院;

关键词：

SARS-CoV-2; antibody; neutralization; severe; non-severe;

D O I：

10.1080/22221751.2020.1823890

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

We studied plasma antibody responses of 35 patients about 1 month after SARS-CoV-2 infection. Titers of antibodies binding to the viral nucleocapsid and spike proteins were significantly higher in patients with severe disease. Likewise, mean antibody neutralization titers against SARS-CoV-2 pseudovirus and live virus were higher in the sicker patients, by similar to 5-fold and similar to 7-fold, respectively. These findings have important implications for those pursuing plasma therapy, isolation of neutralizing monoclonal antibodies, and determinants of immunity.

引用

页码：2091 / 2093

页数：3

共 50 条

[31] Rational optimization of a human neutralizing antibody of SARS-CoV-2
Chen, Jiao
Wu, Fei
Lin, Dan
Kong, Weikang
Cai, Xueting
Yang, Jie
Sun, Xiaoyan
Cao, Peng
COMPUTERS IN BIOLOGY AND MEDICINE, 2021, 135
[32] Finally neutralizing the threat? A novel SARS-CoV-2 vaccine platform that elicits enhanced neutralizing antibody responses
Salamango, Daniel J.
MBIO, 2024, 15 (04):
[33] Kinetics of Neutralizing Antibody Responses Against SARS-CoV-2 Delta Variant in Patients Infected at the Beginning of the Pandemic
Choe, Pyoeng Gyun
Kim, Yuri
Chang, Euijin
Kang, Chang Kyung
Kim, Nam Joong
Cho, Nam-Hyuk
Park, Wan Beom
Oh, Myoung-don
JOURNAL OF KOREAN MEDICAL SCIENCE, 2022, 37 (08)
[34] Neutralizing Antibody Response of Vaccinees to SARS-CoV-2 Variants
Anichini, Gabriele
Terrosi, Chiara
Savellini, Gianni Gori
Gandolfo, Claudia
Franchi, Federico
Cusi, Maria Grazia
VACCINES, 2021, 9 (05)
[35] SARS-CoV-2 breakthrough infections elicit potent, broad, and durable neutralizing antibody responses
Walls, Alexandra C.
Sprouse, Kaitlin R.
Bowen, John E.
Joshi, Anshu
Franko, Nicholas
Navarro, Mary Jane
Stewart, Cameron
Cameroni, Elisabetta
McCallum, Matthew
Goecker, Erin A.
Degli-Angeli, Emily J.
Logue, Jenni
Greninger, Alex
Corti, Davide
Chu, Helen Y.
Veesler, David
CELL, 2022, 185 (05) : 872 - +
[36] SARS-CoV-2 structural features may explain limited neutralizing-antibody responses
Bachmann, Martin F.
Mohsen, Mona O.
Zha, Lisha
Vogel, Monique
Speiser, Daniel E.
NPJ VACCINES, 2021, 6 (01)
[37] Longitudinal SARS-CoV-2 Antibody Avidity Responses in a SARS-CoV-2 Pregnancy Cohort
Cassidy, Arianna
Prahl, Mary
Song, Dongli
Jegatheesan, Priya
Lynch, Kara
Gaw, Stephanie
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2022, 226 (02) : 297 - 298
[38] Discordant neutralizing antibody and T cell responses in asymptomatic and mild SARS-CoV-2 infection
Reynolds, Catherine J.
Swadling, Leo
Gibbons, Joseph M.
Pade, Corinna
Jensen, Melanie P.
Diniz, Mariana O.
Schmidt, Nathalie M.
Butler, David K.
Amin, Oliver E.
Bailey, Sasha N. L.
Murray, Sam M.
Pieper, Franziska P.
Taylor, Stephen
Jones, Jessica
Jones, Meleri
Lee, Wing-Yiu Jason
Rosenheim, Joshua
Chandran, Aneesh
Joy, George
Di Genova, Cecilia
Temperton, Nigel
Lambourne, Jonathan
Cutino-Moguel, Teresa
Andiapen, Mervyn
Fontana, Marianna
Smit, Angelique
Semper, Amanda
O'Brien, Ben
Chain, Benjamin
Brooks, Tim
Manisty, Charlotte
Treibel, Thomas
Moon, James C.
Noursadeghi, Mahdad
Altmann, Daniel M.
Maini, Mala K.
McKnight, Aine
Boyton, Rosemary J.
SCIENCE IMMUNOLOGY, 2020, 5 (54)
[39] Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2
Walls, Alexandra C.
Fiala, Brooke
Schafer, Alexandra
Wrenn, Samuel
Pham, Minh N.
Murphy, Michael
Tse, Longping, V
Shehata, Laila
O'Connor, Megan A.
Chen, Chengbo
Navarro, Mary Jane
Miranda, Marcos C.
Pettie, Deleah
Ravichandran, Rashmi
Kraft, John C.
Ogohara, Cassandra
Palser, Anne
Chalk, Sara
Lee, E-Chiang
Guerriero, Kathryn
Kepl, Elizabeth
Chow, Cameron M.
Sydeman, Claire
Hodge, Edgar A.
Brown, Brieann
Fuller, Jim T.
Dinnon, Kenneth H., III
Gralinski, Lisa E.
Leist, Sarah R.
Gully, Kendra L.
Lewis, Thomas B.
Guttman, Miklos
Chu, Helen Y.
Lee, Kelly K.
Fuller, Deborah H.
Baric, Ralph S.
Kellam, Paul
Carter, Lauren
Pepper, Marion
Sheahan, Timothy P.
Veesler, David
King, Neil P.
CELL, 2020, 183 (05) : 1367 - +
[40] SARS-CoV-2 structural features may explain limited neutralizing-antibody responses
Martin F. Bachmann
Mona O. Mohsen
Lisha Zha
Monique Vogel
Daniel E. Speiser
npj Vaccines, 6

← 1 2 3 4 5 →